Form 8-K - Current report:
SEC Accession No. 0001193125-21-359976
Filing Date
2021-12-17
Accepted
2021-12-17 07:35:55
Documents
13
Period of Report
2021-12-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d270933d8k.htm   iXBRL 8-K 38834
2 EX-99.1 d270933dex991.htm EX-99.1 12550
  Complete submission text file 0001193125-21-359976.txt   187520

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vera-20211217.xsd EX-101.SCH 2875
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vera-20211217_lab.xml EX-101.LAB 18889
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vera-20211217_pre.xml EX-101.PRE 11849
6 EXTRACTED XBRL INSTANCE DOCUMENT d270933d8k_htm.xml XML 3490
Mailing Address 8000 MARINA BOULEVARD, SUITE 120 BRISBANE CA 94005
Business Address 8000 MARINA BOULEVARD, SUITE 120 BRISBANE CA 94005 650-770-0077
Vera Therapeutics, Inc. (Filer) CIK: 0001831828 (see all company filings)

EIN.: 812744449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40407 | Film No.: 211499512
SIC: 2834 Pharmaceutical Preparations